# Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee
Canonical URL: https://biopharmsignal.com/news/SPRO/spero-therapeutics-and-gsk-announce-pivot-po-phase-3-study-for-tebipenem-hbr-stopped-early-for-efficacy-following-review-by-independent-data-monitoring-committee
Ticker: SPRO
Company: Spero Therapeutics
Source: Spero Therapeutics
Published: 2025-05-28 07:00 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><ul type="disc"><li><em>If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs) </em></li><li><em>An estima

## Article Body
If approved, tebipenem HBr could be the first oral carbapenem antibiotic for US patients with complicated urinary tract infections (cUTIs)

An estimated 2.9 million cases of cUTIs are treated annually in the US1 with many cases requiring hospitalization, contributing to over $6 billion per year in...
## Recent Company News
- 2026-07-27 13:00 EST — [Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer](https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-81a269de) — Source: Spero Therapeutics
- 2026-07-14 11:02 EST — [Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-bac-d8d87fa7) — Source: Spero Therapeutics
- 2026-05-13 16:05 EST — [Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-first-quarter-2026-operating-results-and-provides-business-update) — Source: Spero Therapeutics
- 2026-05-05 16:05 EST — [Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/SPRO/spero-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-13-2026) — Source: Spero Therapeutics
- 2026-03-26 16:05 EST — [Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update](https://biopharmsignal.com/news/SPRO/spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-and-provides-a-business-update) — Source: Spero Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)